Abstract Purposeof Review Health disparities are preventable differences in the diagnosis,
treatment, and outcomes of many diseases, including central nervous system (CNS) tumors …

The disease course and clinical outcome for brain tumor patients depend not only on the
molecular and histological features of the tumor but also on the patient's demographics and …

Care for patients with Alzheimer disease and related neurodegenerative causes of dementia
is in the midst of a transformation. Recent advancements in diagnostics and therapeutics …

Adolescents and young adults (AYAs; ages 15–39 years) are a vulnerable population facing
challenges in oncological care, including access to specialized care, transition of care …

Theranostics is a new treatment modality integrating molecular imaging with targeted
radionuclide therapy. Theranostic agents have received regulatory approval for some …

Leptomeningeal metastatic disease (LMD), encompassing entities of 'meningeal
carcinomatosis', neoplastic meningitis' and 'leukaemic/lymphomatous meningitis', arises …

Background Patients with glioblastoma (GBM) often have inaccurate perceptions of
prognosis. Strong religious beliefs have been associated with limited illness understanding …

Biomarker-based clinical trials investigating targeted treatments for brain tumors have
surged due to better access to biomarker testing and a deeper grasp of the molecular basis …

There is major interest in deintensifying therapy for isocitrate dehydrogenase–mutant low-
grade gliomas, including with single-agent cytostatic isocitrate dehydrogenase inhibitors …